Linesight Poised for Future Global Expansion With New CEO
3.2.2021 14:57:00 EET | Business Wire | Press release
Multinational consultancy firm, Linesight, announced today that it is promoting Paul Boylan to the position of Chief Executive Officer (CEO) and welcoming Tom Dempsey as COO.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210203005457/en/
Paul Boylan, Linesight CEO (Photo: Business Wire)
Boylan has been appointed as the new Chief Executive Officer (CEO) and will be taking over from Gerard Campbell who will remain on the Executive Board throughout 2021. Boylan joined Linesight in 2002 and has amassed over twenty-five years of experience in the global construction industry. He has played a pivotal role in growing Linesight’s client base and expanding the company’s reach geographically.
“Gerard Campbell has made an enormous contribution to Linesight over four decades and will continue to provide valuable strategic inputs on our Executive Board in the coming year,” said Boylan “We are focused on building on the strong foundation Gerard has established, working with our highly skilled and committed global teams who are empowered and motivated to collaborate with our clients for success. Our ability to be agile and rapidly respond to market and client needs will remain a key tenet of our strategic and operational approach going forward.”
Tom Dempsey has also recently joined Linesight’s Executive Leadership team as the new Chief Operations Officer (COO). Dempsey has extensive experience in the pharmaceutical and technology sectors and has held a variety of roles, include VP Global Operations, at Hewlett Packard in the Real Estate function. “I am thrilled to be taking on the role of COO and look forward to supporting Linesight’s ambitious goals of becoming a global authority in construction project, program, scheduling and cost management,” said Dempsey “This is truly an exciting time in Linesight’s evolution as an industry innovator.”
Over the past three years Linesight has extensively expanded its client base in several key sectors, including the Data Center, Life Sciences, Commercial, High-Tech Industry and Residential sectors, in its targets regions of the Americas, Europe, APAC and the Middle East. Year on year revenue growth has been profitable at over 20% owing to the explicit and strategic evolution of the company. Linesight now has twenty-two offices worldwide and over seven hundred skilled team members. With new senior leadership in place Linesight is well structured to deliver on its ambitious growth aspirations which include geographical and team expansion to maximize value for their clients.
ENDS
About Linesight
Linesight is a multinational consultancy firm with over 45 years' experience, providing cost, schedule, program and project management services to a multitude of sectors including Life Sciences, Commercial, Data Centers, High-Tech Industrial, Residential, Hospitality, Aviation, Transport and Infrastructure, Healthcare and Retail. Linesight’s specialist project teams, each with specific skills and experience, provide faster project delivery, greater cost efficiency, predictability in project planning and maximum value for money for their clients. For further information, please visit http://www.linesight.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005457/en/
Contact information
Media Contact UK
Stuart Maclure at ing.media for Linesight
T: +44 (0) 207 247 8334
E: stuart.maclure@ing-media.com
Media Contact USA
Cameron Thomas at Verbfactory for Linesight
T: (416) 660-9801
E: cameron@verbfactory.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom